Chronic Obstructive Pulmonary Disease (COPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
-1.jpg)
Chronic Obstructive Pulmonary Disease
(COPD) is a major cause of chronic morbidity and mortality throughout the
world. Many people suffer from this disease for years and die prematurely from
it or its complications. COPD is the fourth leading cause of death in the world
and further increases in its prevalence and mortality can be predicted in the
coming decades. Chronic inflammation causes structural changes and narrowing of
the small airways. Destruction of the lung parenchyma, also by inflammatory
processes, leads to the loss of alveolar attachments to the small airways and
decreases lung elastic recoil; in turn, these changes diminish the ability of
the airways to remain open during expiration. The airflow limitation is best
measured by spirometry, as this is the most widely available, reproducible test
of lung function. The impact of COPD on an individual patient depends not just
on the degree of airflow limitation, but also on the severity of symptoms.
There is only an imperfect relationship between the degree of airflow
limitation and the presence of symptoms. Spirometric staging, therefore, is a
pragmatic approach aimed at practical implementation and should only be
regarded as an educational tool and a general indication of the initial
approach to management.
- The prevalence of COPD in the USA varies from 6% to 11% in
the adult population. The American Lung Association reports ~14 million
American adults had been diagnosed with COPD. However, nearly 24 million
American adults have evidence of impaired lung function, suggesting that
COPD is underdiagnosed.
Thelansis’s “Chronic Obstructive
Pulmonary Disease (COPD) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Chronic
Obstructive Pulmonary Disease (COPD) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Chronic Obstructive Pulmonary Disease (COPD) across 8 MM market from the
centre of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
Chronic Obstructive Pulmonary Disease
(COPD) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment